New Stock News | Autel Intelligent Technology Corp., Ltd. (688208.SH) Hong Kong IPO Prospectus Invalid
The Hong Kong stock prospectus submitted by Shenzhen ETONE Technology Co., Ltd. (referred to as ETONE Technology (688208.SH)) on December 19, 2025, has been valid for 6 months and will expire on December 19, 2026. At the time of submission, China International Capital Corporation Limited was its exclusive sponsor.
Shenzhen Autel Intelligent Technology Corp., Ltd. (referred to as Autel Intelligent Technology Corp., Ltd. (688208.SH)) submitted its Hong Kong IPO prospectus on December 19, 2025, which expired six months later on December 19, 2026, with CICC as its exclusive sponsor.
The prospectus shows that Autel Intelligent Technology Corp., Ltd. is a leading provider of intelligent vehicle diagnosis and smart charging solutions. According to Frost & Sullivan data, in terms of revenue from 2022, 2023, and 2024, the company is the world's largest provider of intelligent vehicle diagnosis solutions, with market share increasing from 9.1% in 2022 to 11.1% in 2024; in terms of overseas revenue in 2024, the company is the largest Chinese smart charging solutions provider in China, and in terms of revenue in 2024, the company is the fourth-largest charging solutions provider in North America, and also the largest Chinese smart charging solutions provider in North America.
The company has established a global sales network covering approximately 100 countries or regions. The sales channels include distribution networks and direct sales channels. The company has collaborated with over 800 distributors worldwide to continuously expand its market coverage and increase market penetration. At the same time, the company collaborates directly with end customers, providing services to top global energy companies, mainstream charging facility operators, automotive diagnostic equipment distributors, and Fortune 500 companies.
Related Articles

CMS(00867): Approval granted for the application for the Chinese market of a type 1 new drug, the recombinant human anti-rabies virus bispecific antibody Semlerweiming monoclonal injection.

On June 22, NEWBORNTOWN (09911) spent approximately 1.9969 million Hong Kong dollars to buy back 242,000 shares.

SHENZHEN INT'L (00152) issued 7.3302 million shares of interest-bearing shares.
CMS(00867): Approval granted for the application for the Chinese market of a type 1 new drug, the recombinant human anti-rabies virus bispecific antibody Semlerweiming monoclonal injection.

On June 22, NEWBORNTOWN (09911) spent approximately 1.9969 million Hong Kong dollars to buy back 242,000 shares.

SHENZHEN INT'L (00152) issued 7.3302 million shares of interest-bearing shares.

RECOMMEND





